Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial-Reference-Cited by-同舟云学术

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

Published:2018-05 Issue:5 Volume:6 Page:337-344
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Calverley Peter M A,Anzueto Antonio R,Carter Kerstine,Grönke Lars,Hallmann Christoph,Jenkins Christine,Wedzicha Jadwiga,Rabe Klaus F

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Acute COPD exacerbations;Wedzicha;Clin Chest Med,2014

2. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary;Vogelmeier;Am J Respir Crit Care Med,2017

3. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study;Decramer;Lancet Respir Med,2013

4. Tiotropium versus salmeterol for the prevention of exacerbations of COPD;Vogelmeier;N Engl J Med,2011

5. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide;Wedzicha;Am J Respir Crit Care Med,2008

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in COPD severe exacerbations, and all-cause and respiratory mortality, before and after implementation of newer long-acting bronchodilators in a large population-based cohort;BMC Pulmonary Medicine;2024-09-13

2. A Pilot Study on Proteomic Predictors of Mortality in Stable COPD;Cells;2024-08-14

3. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study;International Journal of Chronic Obstructive Pulmonary Disease;2024-07

4. Cardiac comorbidity and COPD: chance or consequence?;COPD in the 21st Century;2024-03-01

5. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial;International Journal of Chronic Obstructive Pulmonary Disease;2024-01